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Gemcitabine improves survival 
in patients with recurrent or metastatic 
nasopharyngeal carcinoma
Shaodong Hong1,2 and Li Zhang1,2*
Abstract 
For decades, the selection of chemotherapeutic regimens for the treatment of recurrent or metastatic nasopharyn-
geal carcinoma has been mainly empirical. To our knowledge, there is no phase 3 trial that has been conducted to 
determine the optimal treatment for these patients before our publication. Recently, we published an article in The 
Lancet entitled “Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal 
carcinoma: a multicentre, randomised, open-label, phase 3 trial.”  The results of our study indicate that gemcitabine 
plus cisplatin could improve the survival of patients with recurrent or metastatic nasopharyngeal carcinoma com-
pared with conventional fluorouracil plus cisplatin.
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Background
Nasopharyngeal carcinoma (NPC) is an endemic can-
cer, with the highest incidence in Southeast Asia [1, 2]. 
Radiotherapy or chemoradiotherapy has become the 
primary treatment of early or locoregionally advanced 
NPC [3, 4]. However, about one-third of these patients 
have treatment failure due to distant metastasis [5]. The 
median overall survival (OS) of recurrent or metastatic 
NPC patients is only approximately 20 months [6]. Fluo-
rouracil plus cisplatin is generally regarded as the stand-
ard first-line chemotherapy regimen for these patients, 
although it has never been directly compared with best 
supportive care. However, the fluorouracil regimen is 
limited by the requirement for deep-vein catheterization 
and the short duration of response. Therefore, using care-
fully designed, large clinical trials to find novel agents for 
the treatment of metastatic NPC is of critical importance. 
As such, in our recent Lancet article entitled “Gemcit-
abine plus cisplatin versus fluorouracil plus cisplatin 
in recurrent or metastatic nasopharyngeal carcinoma: 
a multicentre, randomised, open-label, phase 3 trial,” 
[7] we presented the preliminary results of our study of 
the efficacy and safety of two competing cisplatin-based 
combinations—gemcitabine plus cisplatin versus fluoro-
uracil plus cisplatin—in patients with recurrent or meta-
static NPC.
The study was conducted in 22 centers in China. In 
these centers, Epstein-Barr virus is the major etiology 
of NPC. A total of 362 patients were randomized in a 
1:1 ratio to receive either gemcitabine plus cisplatin or 
fluorouracil plus cisplatin for a maximum of six 21-day 
treatment cycles. This was an open-labelled study. The 
primary endpoint was progression-free survival (PFS). 
The key findings were the statistically and clinically sig-
nificant survival improvement of patients who received 
gemcitabine plus cisplatin compared with patients 
who received fluorouracil plus cisplatin, in both PFS 
[median: 7.0 vs. 5.6  months; hazard ratio (HR) 0.55; 
P  <  0.001] and OS (median 29.1 vs. 20.9  months; HR 
0.62; P =  0.003). Although the follow-up time for OS 
was relatively short, the substantial gain in OS might 
be explained by the low crossover rate of 8% to gem-
citabine in the fluorouracil-plus-cisplatin group. Final 
OS results with more in-depth analyses are being 
generated.
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Our exploratory analyses further suggest that the 
improvement of PFS for patients who received gem-
citabine plus cisplatin was consistent across most sub-
groups. However, it should be noted that the enrolled 
patients were from endemic areas, where the primary 
NPC histological classifications are non-keratinizing 
undifferentiated (type III) and non-keratinizing differen-
tiated (type II) diseases. For keratinizing subtype (type I), 
which is more prevalent in Western countries, whether 
gemcitabine is superior to fluorouracil needs more 
investigation. Overall, gemcitabine demonstrated more 
remarkable anti-tumor activity compared with fluoroura-
cil, as seen by the significant improvement in objective 
response rate (64% vs. 42%, P  <  0.001). Disease control 
rates were similarly high in both arms (90% vs. 86%).
The adverse events of both regimens were as expected. 
Patients who received gemcitabine had increased risks 
of grade ≥3 leukopenia, neutropenia, and thrombocyto-
penia, whereas those who received fluorouracil had an 
increased risk of grade ≥3 mucosal inflammation. The 
occurrence rates of serious adverse events were simi-
lar between the two arms (4% in the gemcitabine-plus-
cisplatin group vs. 6% in the fluorouracil-plus-cisplatin 
group).
The next frontier in the treatment of NPC patients will 
entail improved prognosis stratification with existing and 
novel biomarkers and the development of novel drugs 
beyond conventional chemotherapeutics [8].
Conclusions
Our data indicate that, for patients with recurrent or 
metastatic NPC, gemcitabine is superior to fluoroura-
cil in terms of OS and PFS. These results could establish 
gemcitabine plus cisplatin as the new standard first-line 
treatment regimen for this patient population.
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